DBV Technologies (NASDAQ:DBVT – Get Free Report) and Apogee Therapeutics (NASDAQ:APGE – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Risk & Volatility
DBV Technologies has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500.
Profitability
This table compares DBV Technologies and Apogee Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DBV Technologies | -815.73% | -106.07% | -76.17% |
| Apogee Therapeutics | N/A | -21.81% | -20.94% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DBV Technologies | $15.73 million | 4.57 | -$72.73 million | ($4.50) | -0.78 |
| Apogee Therapeutics | N/A | N/A | -$83.99 million | ($2.42) | -20.28 |
DBV Technologies has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings for DBV Technologies and Apogee Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DBV Technologies | 0 | 0 | 2 | 0 | 3.00 |
| Apogee Therapeutics | 0 | 0 | 8 | 0 | 3.00 |
DBV Technologies currently has a consensus target price of $30.00, indicating a potential upside of 759.11%. Apogee Therapeutics has a consensus target price of $83.88, indicating a potential upside of 70.93%. Given DBV Technologies’ higher possible upside, research analysts clearly believe DBV Technologies is more favorable than Apogee Therapeutics.
Institutional & Insider Ownership
71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 1.9% of DBV Technologies shares are held by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Apogee Therapeutics beats DBV Technologies on 8 of the 12 factors compared between the two stocks.
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
About Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
